Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.08 USD | +11.18% | -6.15% | 0.00% |
Apr. 25 | Nasdaq's revenue beats on strong demand for fintech products | RE |
Mar. 26 | Kyverna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | 3.75M | Sales 2025 * | 5M | Capitalization | 546M |
---|---|---|---|---|---|
Net income 2024 * | -130M | Net income 2025 * | -199M | EV / Sales 2024 * | 93.1 x |
Net cash position 2024 * | 197M | Net cash position 2025 * | 142M | EV / Sales 2025 * | 80.8 x |
P/E ratio 2024 * |
-3.98
x | P/E ratio 2025 * |
-3.2
x | Employees | 96 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.27% |
1 day | +11.18% | ||
1 week | -6.15% | ||
Current month | -6.84% | ||
1 month | -42.64% | ||
3 months | -53.14% |
Managers | Title | Age | Since |
---|---|---|---|
Peter Maag
CEO | Chief Executive Officer | 56 | 22-10-12 |
Ryan Jones
DFI | Director of Finance/CFO | 36 | 17-12-31 |
Dominic Borie
CTO | Chief Tech/Sci/R&D Officer | 61 | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Beth Seidenberg
BRD | Director/Board Member | 67 | 18-08-31 |
Ian Clark
CHM | Chairman | 62 | 21-09-14 |
Dan Spiegelman
BRD | Director/Board Member | 65 | 21-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-09 | 14.1 | +11.41% | 126 135 |
24-05-08 | 12.66 | -7.25% | 423,239 |
24-05-07 | 13.65 | -2.22% | 251,900 |
24-05-06 | 13.96 | -8.46% | 238,284 |
24-05-03 | 15.25 | +1.46% | 459,649 |
Delayed Quote Nasdaq, May 09, 2024 at 02:01 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 546M | |
+24.78% | 46.71B | |
+48.83% | 41.8B | |
-1.18% | 41.52B | |
-5.86% | 29.55B | |
+10.69% | 25.78B | |
-20.54% | 19.26B | |
+2.40% | 12.14B | |
-3.52% | 12.08B | |
+28.95% | 11.98B |
- Stock Market
- Equities
- KYTX Stock